Bimatoprost Ophthalmic Solution for Enhanced Eyelash Growth
Bimat
| Product dosage: 0.3mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $60.00 | $60.00 (0%) | 🛒 Add to cart |
| 2 | $50.00 | $120.00 $100.00 (17%) | 🛒 Add to cart |
| 3 | $43.33 | $180.00 $130.00 (28%) | 🛒 Add to cart |
| 4 | $42.50 | $240.00 $170.00 (29%) | 🛒 Add to cart |
| 5 | $40.00 | $300.00 $200.00 (33%) | 🛒 Add to cart |
| 6 | $38.33 | $360.00 $230.00 (36%) | 🛒 Add to cart |
| 7 | $37.14 | $420.00 $260.00 (38%) | 🛒 Add to cart |
| 8 | $36.25 | $480.00 $290.00 (40%) | 🛒 Add to cart |
| 9 | $34.44 | $540.00 $310.00 (43%) | 🛒 Add to cart |
| 10 | $33.00
Best per bottle | $600.00 $330.00 (45%) | 🛒 Add to cart |
Synonyms | |||
Bimatoprost ophthalmic solution 0.03% is a prostaglandin analog prescription medication specifically formulated to treat hypotrichosis of the eyelashes. Its primary mechanism of action involves prolonging the anagen (growth) phase of the eyelash hair cycle, increasing the proportion of hairs in this active phase, and stimulating the development of darker, thicker, and longer lashes. Clinical studies have demonstrated its efficacy and safety profile, making it a cornerstone treatment in ophthalmic and dermatological practices for this cosmetic indication. This product card provides a comprehensive, expert-level overview for healthcare professionals and informed patients.
Features
- Active Pharmaceutical Ingredient: Bimatoprost 0.03% (0.3 mg/mL)
- Pharmacological Class: Synthetic prostaglandin analog
- Formulation: Sterile, isotonic, buffered ophthalmic solution
- Preservative: Benzalkonium chloride 0.05 mg/mL
- Primary Indication: Treatment of hypotrichosis (inadequate or not enough lashes) of the eyelashes
- Presentation: Typically supplied in a 3 mL tinted glass bottle with multiple sterile, single-use applicators
Benefits
- Clinically Proven Efficacy: Significantly increases eyelash prominence, including length, thickness, and darkness, as measured by global eyelash assessment scores.
- Targeted Mechanism: Acts directly on the hair follicle’s prostaglandin receptors to prolong the growth phase, resulting in a higher number of actively growing lashes.
- Predictable and Gradual Results: Visible improvement is typically observed after approximately two months of nightly application, with full results achieved after treatment completion.
- Well-Established Safety Profile: Extensive clinical data supports its use for this indication, with a well-characterized side effect profile primarily limited to the ocular surface.
- Non-Invasive Application: Provides a topical, at-home treatment alternative to more invasive cosmetic procedures like eyelash extensions or tints.
- Reversible Effects: Eyelashes are expected to gradually return to their pretreatment appearance over several weeks to months after discontinuation of therapy, allowing for flexibility in treatment.
Common use
Bimatoprost ophthalmic solution 0.03% is indicated for the topical treatment of hypotrichosis of the eyelashes. It is prescribed to enhance eyelash growth by increasing their length, thickness, and darkness. Patients typically apply the solution once daily to the skin of the upper eyelid margin at the base of the eyelashes using the supplied sterile applicators. It is not intended for application directly into the eye. Treatment is continuous, and results are not permanent; discontinuation will lead to a gradual return of eyelashes to their pretreatment state.
Dosage and direction
The recommended dosage is one application per day to the upper eyelid margin only. More frequent application will not increase efficacy and may increase the risk of adverse reactions.
Directions for Use:
- Ensure face is clean, makeup is removed, and contact lenses are removed (if applicable).
- Remove one sterile applicator from its tray.
- Holding the sterile applicator horizontally, place one drop of the solution on the area of the applicator closest to the tip, but not on the tip itself.
- Immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes, going from the inner part to the outer part of the eyelid. Do not apply to the lower eyelid.
- Blot any excess solution runoff beyond the eyelid margin with a tissue.
- Discard the applicator after a single use. Do not reuse applicators.
- Repeat the process for the opposite upper eyelid margin using a new sterile applicator.
- Do not allow the tip of the bottle to contact surrounding structures, fingers, or any other surface to avoid contamination.
Precautions
- Potential for Iris Pigmentation: Prostaglandin analogs, including bimatoprost, may gradually increase the brown pigmentation of the iris. This change is likely to be permanent and may be more noticeable in patients with mixed-color irides (e.g., blue-brown, green-brown, yellow-brown).
- Potential for Eyelid Skin Darkening: Skin darkening upon which the solution is repeatedly applied may occur and may be reversible upon discontinuation.
- Potential for Hair Growth: Hair growth may occur in skin areas that the solution frequently touches.
- Contamination Risk: Strict aseptic technique is required when handling the solution and applicators to prevent microbial contamination, which could lead to serious ocular infections.
- Contact Lens Wear: Patients should remove contact lenses prior to application. Lenses may be reinserted 15 minutes following application.
- Concurrent Eye Conditions: Use with caution in patients with active intraocular inflammation (e.g., uveitis) or in patients with a torn or absent lens capsule due to the potential for increased macular edema.
Contraindications
Bimatoprost ophthalmic solution 0.03% is contraindicated in patients with a known hypersensitivity to bimatoprost, benzalkonium chloride, or any other component of the product formulation. Signs of hypersensitivity may include ocular erythema, eyelid edema, pruritus, and rash.
Possible side effect
The most common reported adverse reactions (occurring in approximately 3-4% of patients) are conjunctival hyperemia, eyelid skin hyperpigmentation, ocular pruritus, and dry eye symptoms. Other less common side effects include:
- Ocular: Eye irritation, foreign body sensation, conjunctival edema, visual disturbance, blepharitis, cataract, superficial punctate keratitis, eyelash darkening, increased iris pigmentation, eyelid erythema, ocular pain, periorbital erythema.
- Non-ocular: Headaches, asthenia, and hirsutism.
- Serious but rare: Macular edema, including cystoid macular edema, has been reported in susceptible individuals, typically those with a torn posterior lens capsule or aphakic patients. Uveitis and iritis have also been reported infrequently.
Drug interaction
Formal drug interaction studies have not been conducted with topical bimatoprost. However, concomitant administration of other topical ophthalmic agents (e.g., other prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cholinergic agents) should be administered with at least a 5-minute interval between applications to prevent dilution and potential washout of the prior medication. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Missed dose
If a dose is missed, the patient should apply the solution at the next scheduled application time. The patient should not apply a double dose to make up for a missed dose, as this may increase the risk of adverse effects without enhancing efficacy.
Overdose
Topical overdose of bimatoprost is unlikely to produce life-threatening systemic effects due to limited absorption. However, accidental ingestion or ocular exposure to a large volume may lead to systemic prostaglandin-type effects. Symptoms of an ocular overdose may include pronounced conjunctival hyperemia, ocular irritation, and blepharitis. In case of accidental ingestion, standard supportive measures should be employed. Treatment should be symptomatic and supportive. There is no specific antidote.
Storage
Store the product at room temperature between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 2°C to 8°C (36°F to 46°F) and 15°C to 30°C (59°F to 86°F). Protect from light. Keep the bottle tightly closed when not in use. Discard the product four weeks after the bottle is first opened to minimize the risk of contamination and degradation. Keep out of reach of children.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, ophthalmologist, or other qualified health provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read herein. The manufacturer and publisher are not responsible for any errors or omissions or for any consequences from application of the information in this document.
Reviews
- “As an oculoplastic surgeon, I have prescribed bimatoprost for eyelash hypotrichosis for over a decade. The clinical results are consistently impressive and predictable. Patient satisfaction is high, provided they are properly counseled on the slow onset of action and potential for iris pigmentation changes.” – Dr. Eleanor Vance, MD
- “The clinical trial data is robust. The product reliably increases lash length, thickness, and darkness by measurable parameters. It remains the gold-standard pharmacological treatment for this condition.” – Clinical Study Review, Journal of Dermatological Treatment
- “After 16 weeks of consistent use, my eyelashes were significantly longer and fuller. The application process is simple once you get the hang of it. I experienced some mild eyelid redness for the first few weeks, but it subsided.” – Verified Patient
- “It’s crucial for patients to understand this is a long-term commitment and that results are not permanent. Managing expectations is key to a positive therapeutic outcome.” – Dermatology Nurse Practitioner
- “While effective, the cost and the need for ongoing use can be a barrier for some patients. The risk of permanent iris color change, though rare, requires a thorough informed consent process.” – Pharmacist Review